{"cluster": 50, "subcluster": 6, "abstract_summ": " As the COVID-19 pandemic worsens, the clinical cancer community is grappling with how to continue providing access to experimental therapies while keeping immunocompromised patients safe . Cancer centers are making changes to their clinical trial programs, while pharmaceutical companies are deciding how-or whether-trials should continue ."}